Comparing Effects of Tibolone and Estradiol ValerateMedroxyprogesterone on Menopausal Symptoms Including Overactive Bladder, Sexual Function, and Arterial Health

What this Trial Is About

Researchers are evaluating the effects of two hormone therapy regimens on menopausal symptoms such as overactive bladder, sexual function, depression, autonomic function, arterial stiffness, and atherosclerosis. This study compares tibolone to a combination of estradiol valerate and medroxyprogesterone acetate in women with menopausal syndrome who still have an intact uterus. The goal is to better understand how these treatments impact these symptoms and related health measures. The study involves two treatment groups one receiving tibolone 2.5 mg daily, and the other receiving estradiol valerate 1 mg combined with medroxyprogesterone acetate 2.5 mg daily. This open-label, prospective study enrolls women who have been treated for menopausal syndrome starting from October 2021. Participants will take their assigned hormone therapy daily and be evaluated over 12 weeks. Participants will complete several questionnaires and undergo tests to measure symptoms and health effects at the start, 4 weeks, and 12 weeks after beginning treatment. These include assessments of menopausal symptoms, bladder urgency and severity, sexual function, sleep quality, depression, heart rate variability, arterial stiffness, and atherosclerosis. The research team will compare the results between the two hormone therapy groups to assess their impact on these measures.

HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness